Posted on 21 February 2020
Neurodegenerative diseases are associated with the accumulation of harmful molecular waste in the brain, such as amyloid plaque and tau tangles in Alzheimer’s disease. Cerebrospinal fluid carries this waste away as it drains into the body through various channels, but this drainage is impaired with age.
The life sciences company EnClear Therapies has been exploring the possibility that such molecular waste could be filtered out of the cerebrospinal fluid, using a technique similar to blood filtration. They recently announced a $10 million financing, led by 20/20 HealthCare Partners.
The founders of EnClear are focused on producing a technology that could revolutionise the field by allowing fast diagnosis, delivery of any drug directly into the cerebrospinal fluid, and the development of new CNS-focused therapeutics. I am excited to help EnClear grow their business to help the millions of patients living with CNS diseases.Jason Camm, Managing Director and Chief Medical Officer at Thiel Capital
WIRE, B. (2020). EnClear Therapies Announces $10M Series A Financing. Retrieved 21 February 2020, from https://www.businesswire.com/news/home/20200219005179/en/EnClear-Therapies-Announces-10M-Series-Financing
Effective treatments for neurodegenerative diseases are desperately needed, as these conditions remain incurable and efforts to develop effective drugs have so far found little success.
EnClear Therapies Announces $10M Series A Financing: https://www.businesswire.com/news/home/20200219005179/en/EnClear-Therapies-Announces-10M-Series-Financing
EnClear Therapies Raises $10 Million to Develop a Means to Filter Molecular Waste from Cerebrospinal Fluid: https://www.fightaging.org/